Bank Julius Baer & Co. Ltd, Zurich Genenta Science S.P.A. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$3.14 - $4.84 $85,514 - $131,812	-27,234 Reduced 6.6%	385,313 $1.35 Million
Q4 2023 May 16, 2024	BUY	$4.7 - $5.59 $127,999 - $152,238	27,234 Added 7.07%	412,547 $2.04 Million
Q2 2023 Jul 24, 2023	BUY	$5.0 - $6.67 $2.06 Million - $2.75 Million	412,547 New	412,547 $2.46 Million

248K

Ticker GNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,216,900
Market Cap $89.3M
Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.